Anxiety, Autonomic Nervous System Dysfunction, Behavioral Health, Burnout Syndrome, Cognitive Fatigue, Emotional Stress, Financial Stress, Heart Rate Variability, Insomnia, Neurobehavioral Manifestations, Occupational Stress, Psychological Stress, Sleep Disturbance
Conditions
Keywords
NeuroFinance, Financial Stress Medicine, Wearable Biosensors, Artificial Intelligence, Machine Learning, Digital Biomarkers, Heart Rate Variability, Sleep Monitoring, Behavioral Analytics, Cardiovascular Telemetry, Decentralized Clinical Trial, Emotional Resilience, Physiologic Stress, Market Volatility, Economic Uncertainty, Social Media Exposure, Cognitive Performance, Stress Forecasting, Precision Wellness, Remote Patient Monitoring
Brief summary
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a decentralized observational clinical study designed to evaluate how financial market volatility, economic uncertainty, digital media exposure, and information-driven stress environments affect human physiologic and behavioral health. Participants will undergo remote monitoring using wearable biosensors, cardiovascular telemetry devices, sleep tracking systems, heart rate variability monitoring, and behavioral analytics platforms. The study will use artificial intelligence and machine learning systems to analyze relationships between external financial and informational events and biologic stress responses, including autonomic nervous system activity, sleep disruption, cardiovascular strain, emotional resilience, and inflammatory signaling. The goal of the study is to develop predictive digital biomarkers and AI-assisted forecasting systems capable of identifying stress-related physiologic deterioration before clinical manifestation.
Detailed description
The NeuroFinance Human Stress Trial (NFHST-2026-001) is a prospective, decentralized observational study designed to evaluate physiologic and behavioral responses associated with exposure to financial market volatility, economic uncertainty, and digitally mediated informational stress environments. Participants will undergo remote monitoring using commercially available wearable biosensor technologies and digital health platforms. Data collection may include continuous or intermittent monitoring of: Heart rate variability (HRV) Resting heart rate Sleep duration and sleep efficiency Blood pressure measurements Physical activity metrics Galvanic skin response Voice-based behavioral analytics Optional electrocardiographic monitoring Environmental and informational exposure datasets may include: Financial market volatility indices News sentiment datasets Social media exposure metrics Economic uncertainty indicators Behavioral interaction telemetry Artificial intelligence and machine learning systems may be used for exploratory correlation analyses between physiologic biomarkers and external informational stressors. No investigational drug or invasive intervention will be administered as part of this observational study. Optional biologic sampling may include saliva-based inflammatory biomarker collection and participant-reported psychometric assessments. Primary analyses will evaluate longitudinal changes in physiologic stress-related biomarkers during periods of elevated informational or financial stress exposure. Secondary analyses will evaluate associations between physiologic variability, behavioral adaptation metrics, sleep disruption, and cognitive performance measures. The study is intended to support development of digital biomarker methodologies and decentralized monitoring frameworks for stress-related physiologic research.
Interventions
DEVICEWearable Physiologic Monitoring Platform
Commercially available wearable physiologic monitoring devices and digital health technologies will be used to collect continuous or intermittent biometric, cardiovascular, autonomic nervous system, behavioral, and sleep-related data during exposure to financial market volatility, economic uncertainty, and information-driven stress environments. Monitoring technologies may include: wearable ECG devices, heart rate variability (HRV) monitors, blood pressure monitoring systems, sleep tracking devices, galvanic skin response sensors, activity monitoring wearables, voice analysis systems, and optional EEG-enabled wearable technologies. Data generated from these systems will be integrated with artificial intelligence and machine learning-based analytics platforms for evaluation of physiologic stress responses and digital biomarker forecasting.
Sponsors
Truway Health, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Adults age 18 years and older. * Ability to provide informed consent. * Willingness and ability to comply with study procedures and remote monitoring requirements. * Access to a compatible smartphone, tablet, or internet-connected device for decentralized study participation. * Willingness to utilize wearable physiologic monitoring technologies during the study period. * Participants with varying degrees of financial market exposure, occupational stress exposure, or digital media exposure are eligible. * Healthy volunteers and participants with self-reported stress-related symptoms may be enrolled. * Ability to read and understand English-language consent and study materials.
Exclusion criteria
* Individuals unable or unwilling to provide informed consent. * Individuals unable to comply with remote monitoring procedures or wearable device usage requirements. * Active medical or psychiatric instability that, in the opinion of study investigators, may interfere with study participation or data integrity. * Current incarceration or institutionalization limiting voluntary participation. * Participation in another interventional clinical trial that may substantially interfere with physiologic monitoring outcomes. * Any condition that would significantly impair safe study participation as determined by the study investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Heart Rate Variability (HRV) During Financial Stress Exposure | Baseline through 24 Months | Heart rate variability will be measured using wearable electrocardiographic or photoplethysmographic monitoring devices. HRV will be quantified as the root mean square of successive differences (RMSSD) in milliseconds. Higher RMSSD values generally indicate improved autonomic nervous system flexibility and lower physiologic stress burden. |
| Change in Sleep Duration | Baseline through 24 Months | Sleep duration will be measured in hours per night using wearable sleep monitoring devices. |
| Change in Resting Heart Rate | Baseline through 24 Months | Resting heart rate will be measured in beats per minute using wearable biosensor devices. |
| Change in Perceived Stress Scale-10 (PSS-10) Total Score | Baseline through 24 Months | Perceived stress will be assessed using the validated 10-item Perceived Stress Scale-10 questionnaire. Scores range from 0 to 40, with higher scores indicating greater perceived psychological stress and worse stress-related outcomes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Sleep Efficiency | Baseline through 24 Months | Sleep efficiency percentage measured using wearable sleep tracking systems. |
| Change in Galvanic Skin Response (GSR) Measurements | Baseline through 24 Months | Electrodermal activity will be measured in microsiemens using wearable biosensor devices to assess sympathetic nervous system activation and physiologic stress responsiveness. Higher values may reflect increased autonomic arousal during stress exposure conditions. |
| Change in Generalized Anxiety Disorder-7 (GAD-7) Total Score | Baseline through 24 Months | Anxiety symptoms will be assessed using the validated Generalized Anxiety Disorder-7 questionnaire. Scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity and worse psychological outcomes. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORGavin C Solomon, Investigator
Truway Health, Inc.
Outcome results
None listed